β2 spectrin-mediated differentiation repressed the properties of liver cancer stem cells through β-catenin

Area of Science:

• Hepatology
• Molecular Biology
• Cancer Research

Background:

• Dedifferentiation is a hallmark of cancer progression in hepatocellular carcinoma (HCC).
• BetaII-Spectrin (β2SP) acts as a Smad3/4 adaptor protein in the transforming growth factor (TGF)-β/Smad signaling pathway and is implicated in suppressing hepatocarcinogenesis.
• Down-regulation of β2SP is observed in cirrhotic liver and HCC, suggesting a role in tumorigenesis.

Purpose of the Study:

• To investigate if the disruption of β2SP contributes to HCC tumorigenesis via dedifferentiation.
• To explore the therapeutic potential of restoring β2SP in HCC treatment.

Main Methods:

• Assessed β2SP expression levels in cirrhotic liver, HCC tissues, and a rat model of hepatocarcinogenesis.
• Investigated the effect of transgenic β2SP expression on HCC cell differentiation and growth in vitro.
• Examined the impact of β2SP transduction on liver cancer stem cell (CSC) properties, including colony formation, spheroidization, invasion, chemo-resistance, and tumorigenicity in vivo.
• Analyzed the role of β-catenin in mediating β2SP effects in liver CSCs.

Main Results:

• β2SP expression was down-regulated in cirrhotic liver and HCC and correlated with hepatocyte differentiation status.
• Transgenic expression of β2SP promoted HCC cell differentiation and suppressed their growth in vitro.
• Restoring β2SP in liver CSCs reduced their stemness properties (colony formation, spheroidization, invasion, chemo-resistance) and in vivo tumorigenicity.
• β2SP exerted its effects on liver CSCs through the β-catenin pathway.

Conclusions:

• β2SP plays a crucial role in suppressing HCC by inducing differentiation and repressing liver CSC properties.
• Strategies aimed at restoring β2SP levels and activity represent a novel approach for HCC prevention and differentiation therapy.